Lower postprandial glucose responses at baseline and after 4 weeks use of a diabetes-specific formula in diabetes type 2 patients

Diabetes Research and Clinical Practice

Volumn 93, Issue 3, 2011, Pages 421-429

  Lansink, Mirian ^a   van Laere, Katrien M J ^a   Vendrig, Lizeth ^b   Rutten, Guy E H M ^b  

^a DANONE RESEARCH   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Diabetes specific formula; Longer term; Postprandial glucose; Supplementation

Indexed keywords

CHOLESTEROL; FRUCTOSAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES SPECIFIC FORMULA; DIABETIC DIET; DIETARY FIBER; DOUBLE BLIND PROCEDURE; FEMALE; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTERVENTION STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL TOLERANCE; OUTCOME ASSESSMENT; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 80052744917     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.05.019     Document Type: Article

References (39)

1. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7.
2. Woerle H.J., Neumann C., Zschau S., Tenner S., Irsigler A., Schirra J., et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007, 77:280-285.
3. de Vegt F., Dekker J.M., Ruhe H.G., Stehouwer C.D., Nijpels G., Bouter L.M., et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999, 42:926-931.
4. Meigs J.B., Nathan D.M., D'Agostino R.B., Wilson P.W. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002, 25:1845-1850.
5. Cavalot F., Petrelli A., Traversa M., Bonomo K., Fiora E., Conti M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006, 91:813-819.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
7. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
8. Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.
9. International Diabetes Federation. Guideline for management of postmeal glucose; 2007. p. 1-32.
10. Dickinson S., Brand-Miller J. Glycemic index, postprandial glycemia and cardiovascular disease. Curr Opin Lipidol 2005, 16:69-75.
11. Barclay A.W., Petocz P., McMillan-Price J., Flood V.M., Prvan T., Mitchell P., et al. Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr 2008, 87:627-637.
12. Elia M., Ceriello A., Laube H., Sinclair A.J., Engfer M., Stratton R.J. Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes: a systematic review and meta-analysis. Diabetes Care 2005, 28:2267-2279.
13. Mann J.I., De Leeuw I., Hermansen K., Karamanos B., Karlstrom B., Katsilambros N., et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004, 14:373-394.
14. Dahlqvist A., Auricchio S., Semenza G., Prader A. Human intestinal disaccharidases and hereditary disaccharide intolerance. The hydrolysis of sucrose, isomaltose, palatinose (isomaltulose), and a 1,6-alpha-oligosaccharide (isomalto-oligosaccharide) preparation. J Clin Invest 1963, 42:556-562.
15. Kawai K., Yoshikawa H., Murayama Y., Okuda Y., Yamashita K. Usefulness of palatinose as a caloric sweetener for diabetic patients. Horm Metab Res 1989, 21:338-340.
16. Lina B.A., Jonker D., Kozianowski G. Isomaltulose (Palatinose): a review of biological and toxicological studies. Food Chem Toxicol 2002, 40:1375-1381.
17. Severijnen C., Abrahamse E., van der Beek E.M., Buco A., van de Heijning B.J., van Laere K., et al. Sterilization in a liquid of a specific starch makes it slowly digestible in vitro and low glycemic in rats. J Nutr 2007, 137:2202-2207.
18. Vanschoonbeek K., Lansink M., van Laere K.M., Senden J.M., Verdijk L.B., van Loon L.J. Slowly digestible carbohydrate sources can be used to attenuate the postprandial glycemic response to the ingestion of diabetes-specific enteral formulas. Diabetes Educ 2009, 35:631-640.
19. Ceriello A., Lansink M., Rouws C.H., van Laere K.M., Frost G.S. Administration of a new diabetes-specific enteral formula results in an improved 24h glucose profile in type 2 diabetic patients. Diabetes Res Clin Pract 2009, 84:259-266.
20. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
21. Magnoni D., Rouws C.H., Lansink M., van Laere K.M., Campos A.C. Long-term use of a diabetes-specific oral nutritional supplement results in a low-postprandial glucose response in diabetes patients. Diabetes Res Clin Pract 2008, 80:75-82.
22. Grupp U., Siebert G. Metabolism of hydrogenated palatinose, an equimolar mixture of alpha-Dglucopyranosido-1,6-sorbitol and alpha-Dglucopyranosido-1,6-mannitol. Res. Exp. Med. (Berl.) 1978, 173:261-278.
23. Kawai K., Okuda Y., Yamashita K. Changes in blood glucose and insulin after an oral palatinose administration in normal subjects. Endocrinol. Jpn. 1985, 32:933-936.
24. Holub I., Gostner A., Theis S., Nosek L., Kudlich T., Melcher R., et al. Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose). Br J Nutr 2010, 103:1730-1737.
25. Gannon M.C., Nuttall F.Q., Lane J.T., Burmeister L.A. Metabolic response to cottage cheese or egg white protein, with or without glucose, in type II diabetic subjects. Metabolism 1992, 41:1137-1145.
26. Frid A.H., Nilsson M., Holst J.J., Bjorck I.M. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 2005, 82:69-75.
27. Nuttall F.Q., Mooradian A.D., Gannon M.C., Billington C., Krezowski P. Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. Diabetes Care 1984, 7:465-470.
28. Severijnen C., van der Beek E.M., Hageman R., van Laere K., van der Heijning B. Amelioration of fasting plasma glucose levels in diabetic rats after two weeks on an aspartate-rich diet. 25th International Symposium on Diabetes and Nutrition (DNSG) 2007.
29. Harder H., Dinesen B., Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2004, 28:180-182.
30. Yip I., Go V.L., DeShields S., Saltsman P., Bellman M., Thames G., et al. Liquid meal replacements and glycemic control in obese type 2 diabetes patients. Obes Res 2001, 9(Suppl. 4):341S-347S.
31. Riccardi G., Rivellese A.A., Giacco R. Role of glycemic index and glycemic load in the healthy state, in prediabetes, and in diabetes. Am J Clin Nutr 2008, 87:269S-274S.
32. Jarvi A.E., Karlstrom B.E., Granfeldt Y.E., Bjorck I.E., Asp N.G., Vessby B.O. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 1999, 22:10-18.
33. Arai H., Mizuno A., Sakuma M., Fukaya M., Matsuo K., Muto K., et al. Effects of a palatinose-based liquid diet (Inslow) on glycemic control and the second-meal effect in healthy men. Metabolism 2007, 56:115-121.
34. Puckett S.W., Reddy W.J. A decrease in the malate-aspartate shuttle and glutamate translocase activity in heart mitochondria from alloxan-diabetic rats. J Mol Cell Cardiol 1979, 11:173-187.
35. Sakuma M., Arai H., Mizuno A., Fukaya M., Matsuura M., Sasaki H., et al. Improvement of glucose metabolism in patients with impaired glucose tolerance or diabetes by long-term administration of a palatinose-based liquid formula as a part of breakfast. J Clin Biochem Nutr 2009, 45:155-162.
36. Sun J., Wang Y., Chen X., Chen Y., Feng Y., Zhang X., et al. An integrated intervention program to control diabetes in overweight Chinese women and men with type 2 diabetes. Asia Pac J Clin Nutr 2008, 17:514-524.
37. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
38. van Can J.G., Ijzerman T.H., van Loon L.J., Brouns F., Blaak E.E. Reduced glycaemic and insulinaemic responses following isomaltulose ingestion: implications for postprandial substrate use. Br J Nutr 2009, 102:1408-1413.
39. Arai H., Mizuno A., Matsuo K., Fukaya M., Sasaki H., Arima H., et al. Effect of a novel palatinose-based liquid balanced formula (MHN-01) on glucose and lipid metabolism in male Sprague-Dawley rats after short- and long-term ingestion. Metabolism 2004, 53:977-983.